Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02205138 | Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion | PHASE2 | COMPLETED | 38 | — | — | Oct 1, 2014 | Jan 25, 2021 | Jan 29, 2021 | 8 | Belgium |
| Arm | Type | Description |
|---|---|---|
| ALLOB® cells with ceramic scaffold | EXPERIMENTAL | ALLOB® cells with ceramic scaffold Implantation |
| Name | Type | Description |
|---|---|---|
| ALLOB® cells with ceramic scaffold | DRUG | Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia |
Inclusion Criteria: * Ability to provide a written, dated, and signed informed consent prior to any study related procedure, and to understand and comply with study requirements * Symptomatic degenerative disc disease of the lumbar spine requiring a single level lumbar fusion (L1-S1) * Unresponsive...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Mesoblast Limited Sponsored ADR | MESO | 1 | PHASE3 | Rexlemestrocel-L + HA mixture, Saline |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
| Stryker Corporation | SYK | 2 | NA | Undisclosed |
| Globus Medical Inc Class A | GMED | 6 | — | Undisclosed |
| Orthofix Medical, Inc. | OFIX | 1 | — | Undisclosed |